Scientific Liaison Coalition (SLC) Annual Report
June 2015–2016

Current Participating SLC Organizations

American Association for Cancer Research (AACR)
American Academy of Clinical Toxicology (AACT)
American College of Medical Toxicology (ACMT)
American College of Toxicology (ACT)
The Endocrine Society (ENDO)
Environmental Mutagenesis and Genomics Society (EMGS)
International Society for the Study of Xenobiotics (ISSX)
Safety Pharmacology Society (SPS)
Society of Environmental Toxicology and Chemistry (SETAC)
Society of Risk Analysis (SRA)
Society of Toxicologic Pathology (STP)
Society of Toxicology (SOT)
Teratology Society (Teratology)

Current SLC Governance Committee (SLCGC)

Donna L. Mendrick (SOT), Chair
Mary Alice Smith (Teratology), Incoming Chair
Florence G. Burleson (ACT), Immediate Past Chair
Mary Jeanne Kallman, (SPS) Past Chair
Rosalie K. Elespuru (EMGS), Society Representative
Rosonalnd R. Bell (SOT Council Contact), Society Representative
Kenneth L. Hastings (SOT), Society Representative
Thomas B. Knudsen (Teratology), Society Representative, At-Large
Kenneth E. McMartin (AACT), Society Representative
Marcia G Lawson (AIM, Inc.), SLC Administrator
Current SLC Representatives

AACR: Thomas W. Kensler

AACT: Kenneth E. McMartin

ACMT: Stephen Munday
      Suzanne R. White

ACT: Hanan N. Ghantous
      Joe Francisco
      Sharmilee Sawant

EMGS: Rosalie K. Elespuru
      Catherine F. Gibbons

ISSX: Steven C. Kemp

SPS: Gregory S. Friedrichs
     Mary Jeanne Kallman

SETAC: Patrick D. Guiney

SRA: John R. Fowle, III

STP: Susan Eighme Hart
     Arun Pandiri
     Charles Wood

SOT: Kenneth L. Hastings
     Laurie C. Haws
     Paul B. Watkins

At-Large: Thomas B. Knudsen
          Donna Mendrick

Teratology: John M. DeSesso
           Tacey E.K. White
SLC Charge:

Mission: A partnership of scientific societies with the goal of improving public health through a collaborative interdisciplinary approach.

- Strengthening partnerships among scientific, biomedical, and other health-based organizations to increase awareness of the impact of toxicology, diseases, and related subjects on human health.

- Functioning as a means to enhance cooperation among societies as equals with the goal of accomplishing tasks benefiting human health and disease prevention through joint and shared activities.

Cutting-Edge Scientific Exchanges

The representatives of the participating societies of the SLC hold a conference call on the second Tuesday of each month to share topics of mutual interest and to plan for collaborative endeavors aligned with the mission of the SLC. From these conference calls and the twice yearly face-to-face meetings, the SLC representatives have fostered the development and implementation of an array of activities that benefit all of the members of this ad hoc coalition.

Benefits of Membership

- Education
  - Develop educational opportunities through collaborative interactions of webinars, sessions, and courses
  - Obtain access to sessions/programs developed by other SLC representatives
    - Reduced registration to SOT Contemporary Concepts of Toxicology (CCT) meetings
    - Access to live webinars

- Networking Opportunities
  - Develop contacts across scientific groups with whom you may or may not normally interact
Raising Awareness About the SLC

The SLC website (www.toxicology.org/slc.asp) launched in 2014 has grown to include all the SLC webinar recordings. These recordings are freely accessible, demonstrating the SLC commitment to sharing knowledge to improve human and environmental health.

For the SOT 2016 Annual Meeting, the SLC again participated in the SOT Global Gallery of Toxicology, which included 35 societies from around the world. The poster developed for this event is available to travel to the meetings of the representative societies. In addition, SLC leadership attended the IUTOX Global Collaboration Coffee that provided opportunities for networking with the leadership of these societies.

The SLC is reaching out to disease-centric and other societies to encourage their membership.

Three hundred scientists from around the globe participated in the SOT FutureTox III Bridges for Translation, Transforming 21st Century Science into Risk Assessment and Regulatory Decision-Making conference. Held November 19–20, 2015, this international congress drew scientists from across the United States and around the globe, including from Canada, China, Denmark, Germany, Italy, Japan, Mexico, Nigeria, South Korea, the United Kingdom, and Switzerland. This meeting was conceived by the Scientific Liaison Coalition and was organized under the auspices of the SOT Contemporary Concepts in Toxicology (CCT) Conferences Committee.
SOT 2015–2016 President Peter L. Goering noted in his message to attendees, “Building on the successful outcomes of two earlier conferences, FutureTox (2012) and FutureTox II (2014), FutureTox III brings together distinguished experts and attendees from academia, industry, and government. We are continuing our journey across the “bridge of translation” by capitalizing on the scientific breakthroughs in high-throughput in vitro data collection and in silico models to advance the risk assessment paradigm.”

The conference Keynote Speakers provided their perspectives on this topic to kick-off this two-day meeting. Jim Jones (left), Assistant Administrator, US Environmental Protection Agency, Washington, DC, addressed “Agency Perspective on 21st Century Approaches in Regulatory Decisions” and Maurice Whelan (right) European Commission Joint Research Centre, Ispra, Italy, “High Throughput Risk Assessment—What’s It Good For?”

This international congress included platform presentations, 100 abstracts, more than 80 posters, and lively breakout sessions on Drug Development, Identifying Endocrine Active Chemicals for Environmental Health Protection Using Pathways-Based Approaches for Screening and Testing, TSCA Reform, and Impact on Global Harmonization. The Poster Reception was a highlight of the meeting and provided the opportunity to honor graduate students and postdoctoral scholars who explored diverse scientific areas related to this overarching topic.

The FutureTox III Organizing Committee was chaired by Daland R. Juberg, Dow AgroSciences. Thomas B. Knudsen, US Environmental Protection Agency, served as the co-chair and other members included Richard A. Becker, American Chemistry Council;
Elaine M. Faustman, University of Washington, Suzanne Compton Fitzpatrick, US Food and Drug Administration; John R. “Jack” Fowle III, Science to Inform; Thomas Hartung, Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing; Ronald N. Hines, US Environmental Protection Agency; Douglas A. Keller, Sanofi; Emmanuel Lemazurier, INERIS-Chronic Risk Division; John C. Lipscomb, US Environmental Protection Agency; Donna Mendrick, US Food and Drug Administration; Raymond R. Tice, National Institute of Environmental Health Sciences (retired); David Watson, Lhasa Limited; Alison Harrill, University of Arkansas for Medical Sciences, CCT Committee Liaison; and George P. Daston, Procter & Gamble Company, SOT Council Contact. Based on the results of the conference survey, there is great interest in a follow-up meeting. The responses noted that FutureTox III provided an excellent update on the new methods and approaches and that future meeting(s) should address how Tox21 will be used, including the opportunities and challenges ahead for implementation.

**SLC Webinar Series**

**Precision Medicine—Getting Personal on Safety**
Tuesday, March 1, 2016, from 11:00 AM–12:30 PM ET

**Presented by:** Sian Ratcliffe, PhD, General Toxicology Site Lead in Drug Safety R&D at Pfizer, Groton, Connecticut, USA. Prior to holding her current role, Dr. Ratcliffe was the Global Head of Safety Pharmacology. Dr. Ratcliffe has a keen research interest in precision medicine, translational and predictive safety projects, and is actively engaged with the US Food and Drug Administration and the National Cancer Institute on PredicTox, a systems pharmacology project to examine cardiotoxicity associated with tyrosine kinase inhibitors.

**Industry Perspective on Biomarkers: The Use of Biomarkers in Clinical Development of Novel Drugs**
Wednesday, October 28, 2015, 11:00 AM–12:30 PM ET USA

**Presented by:** Gene Marcantonio, MD, PhD, Associate Vice President, Translational Pharmacology at Merck Research Laboratories (MRL). Dr. Marcantonio provided an overview of how biomarkers are used in clinical trials in the pharmaceutical industry. Most of the discussion focused on fit for purpose biomarkers developed in order to make critical decisions in early drug development. He discussed the role of target engagement markers to set dose ranges in order to build adequate clinical safety margins. Furthermore, the role of these target engagement markers in determining the level of engagement necessary to translate from a preclinical proof of concept (POC) into a clinical POC study was discussed.
Biomarker Utility and Acceptance in Drug Development and Clinical Trials: An FDA Regulatory Perspective
Tuesday, September 8, 2015, from 11:00 AM–12:30 PM ET USA

Presented by: Shashi Amur, PhD, Scientific Lead of the Biomarker Qualification Program in the Office of Translational Sciences, Center for Drug and Evaluation Research (CDER), US Food and Drug Administration (FDA) and Christopher L. Leptak, MD, PhD, Biomarker and Companion Diagnostics Lead for the Office of New Drugs within CDER/FDA and Co-Director of the Biomarker Qualification Program. Dr. Amur's current research interests include biomarkers in Autoimmune Diseases and in Alzheimer’s disease, drug-induced liver toxicity, pharmacogenomics, and HLA-associated adverse events. The focus of Dr. Leptak's work is on biomarker development and diagnostic device utility in clinical trials and drug development, both for drug-specific programs as well as qualification.

Upcoming Conference:
SOT Contemporary Concepts in Toxicology (CCT) Conference: Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic Metabolic Syndrome: Causes, Risks, Prevention, and Treatment, March 11, 2017, Baltimore, Maryland.

Current Webinars Series:
An SLC Work Group comprised of Mary Jeanne Kallman, SPS; Donna Mendrick, SOT; and Arun Pandiri, STP, has developed a Use of Animal Models of Disease for Toxicity Prediction Webinar Series. This series will provide pharmaceutical industry and regulatory perspectives on this topic. The dates and speakers are listed below: All webinars are from 11:00 am–12:30 pm ET.

- May 17: Diann Blanset, Boehringer Ingelheim
- May 31: Sruthi King, US Food and Drug Administration
- June 21: Sherry Morgan, AbbieVie

Current Working Groups
- FutureTox IV
- Metabolic Syndrome
- Microbiome
- Vaccination
Face-to-Face Meetings and Monthly Conference Calls

- Sunday, March 11, 2012 in conjunction with SOT 2012 Annual Meeting, San Francisco, California
- Wednesday, November 14, 2012, Marriott Wardman Park, Washington, DC
- Sunday, March 10, 2013, Grand Hyatt, San Antonio, Texas
- Wednesday, October 2, 2013, Association Innovation and Management Headquarters, Reston, Virginia
- Sunday, March 23, 2014, Sheraton Phoenix Downtown Hotel, Phoenix, Arizona
- Friday, October 17, 2014, Marriott Wardman Park Hotel, Washington, DC
- Sunday, March 22, 2015, San Diego Convention Center, San Diego, California
- Wednesday, November 18, 2015, Hilton Crystal City at Washington Reagan National Airport, Arlington, Virginia
- Sunday, March 13, 2016, Ernest N. Morial Convention Center, New Orleans, Louisiana

Monthly conference calls are held on the second Tuesday of each month from 1:00 pm–2:00 pm (Eastern Time Zone). These calls are hosted by the Society of Toxicology.